Thomson Reuters Acquires Entagen, Builds Cortellis Data Fusion Technology

February 19, 2014

The press release on titled Thomson Reuters Cortellis Data Fusion Addresses Big Data Challenges by Speeding Access to Critical Pharmaceutical Content announces the embrace of big data by revenue hungry Thomson Reuters. The new addition the suite of drug development technologies will offer users a more intuitive interface through which they will be able to analyze large volumes of data. Chris Bouton, General Manager at Thomson Reuters Life Sciences is quoted in the article,

“Cortellis Data Fusion gives us the ability to tie together information about entities like diseases and genes and the connections between them. We can do this from Cortellis data, from third party data, from a client’s internal data or from all of these at the same time. Our analytics enable the client to then explore these connections and identify unexpected associations, leading to new discoveries… driving novel insights for our clients is at the very core of our mission…”

The changes at Thomson Reuters are the result of the company’s acquisition of Entagen, according to the article. That company is a leader in the field of semantic search and has been working with biotech and pharmaceutical companies offering both development services and navigation software. Cortellis Data Fusion promises greater insights and better control over the data Thomson Reuters holds, while maintaining enterprise information security to keep the data safe.

Chelsea Kerwin, February 19, 2014

Sponsored by, developer of Augmentext


Comments are closed.

  • Archives

  • Recent Posts

  • Meta